Orforglipron shows weight and glucose advantages over oral semaglutide in indirect comparison
pharmafile | October 23, 2026 | News story | | Diabetes, Obesity, Peptide therapies, clinical trials, diabetes, weight reduction
Pharmaceutical firm Lilly’s orforglipron was associated with greater reductions in body weight and blood glucose than oral semaglutide in adults with type 2 diabetes (T2D) who were overweight or had obesity, according to an indirect treatment comparison presented at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026.
The analysis compared data from the phase 3 ACHIEVE-3 and PIONEER-PLUS trials, evaluating orforglipron 17.2mg against oral semaglutide 25mg over 52 weeks.
Orforglipron was associated with a 1.46 percentage point greater reduction in body weight and a 0.31 percentage point greater reduction in glycated haemoglobin (HbA1c), a measure of average blood glucose. Both differences were statistically significant, with findings consistent across multiple sensitivity analyses.
Both treatments are oral glucagon-like peptide-1 (GLP-1) receptor agonists, but orforglipron is a small-molecule, non-peptide therapy that can be taken without food or water restrictions. Oral semaglutide has specific administration requirements, making dosing flexibility a potential differentiator.
Maria Alexandrovich, Pharma Analyst at GlobalData, said the findings could strengthen Lilly’s position in the oral GLP-1 market, while cautioning that the indirect comparison did not establish the clinical significance of the differences.
“Direct head-to-head studies and longer-term outcomes are needed to establish the clinical significance of these differences,” she said.
“Overall, the findings support orforglipron as a competitive oral GLP-1 option in T2D, combining strong glycemic control and weight-loss efficacy with simpler daily administration. Longer-term evidence will help determine whether these advantages translate into improved outcomes in clinical practice.”
Pic: I Yunmai
Related Content
First 90 days of antipsychotic treatment linked to rapid metabolic changes
The first 90 days after starting antipsychotic treatment are a critical period for monitoring blood …
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
Boehringer Ingelheim’s investigational survodutide produced weight loss of up to 13.1% after 76 weeks in …
AstraZeneca’s tozorakimab cuts COPD exacerbations by up to 34% in phase 3 trials
AstraZeneca’s tozorakimab reduced moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease (COPD) in two …
